Anthera Pharmaceuticals Inc
Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clini… Read more
Anthera Pharmaceuticals Inc (ANTH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2018: -1.718x
Based on the latest financial reports, Anthera Pharmaceuticals Inc (ANTH) has a cash flow conversion efficiency ratio of -1.718x as of March 2018.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.38 Million) by net assets ($5.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anthera Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2017)
This chart illustrates how Anthera Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Anthera Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anthera Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NEW MAURITIUS HOTELS LTD
SEM:NMHL-O
|
N/A |
|
Relevant Gold Corp
PINK:RGCCF
|
-1.118x |
|
PHINMA Corp
PSE:PHN
|
0.146x |
|
Crescent Steel & Allied Products Ltd
KAR:CSAP
|
-0.106x |
|
Royal Palms Beach Hotels PLC
CM:RPBHN0000
|
N/A |
|
Alexandria Spinning & Weaving (SPINALEX)
EGX:SPIN
|
N/A |
|
Blockchain Coinvestors Acquisition Corp. I Warrant
NASDAQ:BCSAW
|
0.045x |
|
WASION GROUP HLDGS
BE:W1U
|
N/A |
Annual Cash Flow Conversion Efficiency for Anthera Pharmaceuticals Inc (2007–2017)
The table below shows the annual cash flow conversion efficiency of Anthera Pharmaceuticals Inc from 2007 to 2017.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2017-12-31 | $-5.50 Million | $-36.90 Million | 6.715x | +271.18% |
| 2016-12-31 | $12.47 Million | $-48.92 Million | -3.923x | -403.35% |
| 2015-12-31 | $39.66 Million | $-30.91 Million | -0.779x | -106.88% |
| 2014-12-31 | $-2.26 Million | $-25.60 Million | 11.323x | +623.64% |
| 2013-12-31 | $14.76 Million | $-31.91 Million | -2.162x | -110.35% |
| 2012-12-31 | $-3.53 Million | $-73.64 Million | 20.883x | +645.44% |
| 2011-12-31 | $19.08 Million | $-73.07 Million | -3.829x | -689.20% |
| 2010-12-31 | $57.26 Million | $-27.78 Million | -0.485x | -134.69% |
| 2009-12-31 | $-12.28 Million | $-17.17 Million | 1.399x | -96.24% |
| 2008-12-31 | $-460.26K | $-17.12 Million | 37.207x | +1359.21% |
| 2007-12-31 | $-5.86 Million | $-14.95 Million | 2.550x | -- |